



# SWOG Procedures for Submission and Review of Data Requests

Presented by: Shay Bellasea



# SWOG Data Request Process

- SWOG makes research data available to:
  - Investigators – both SWOG members and external investigators.
  - Pharmaceutical companies.
- Data requests that include study endpoints will only be considered after the primary study analyses have been published.
- An investigator who wishes to use a SWOG dataset must make a formal request which is evaluated by the SWOG Executive Committee (EC). Upon approval, investigators will receive a SWOG EC letter of support.
- In addition to SWOG EC review and approval, the requesting investigator must also sign a Data Use Agreement (DUA) between the Investigator's Institution and SWOG.



# SWOG Data Request Process

## SWOG Data Sharing Request Template

- Accessible on the SWOG website, or via request to the Disease Committee Statistician or the SWOG Network Operations Center at [protocols@swog.org](mailto:protocols@swog.org).
- Key Items to Focus On:
  1. Thoughtful specification of objectives
  2. Assess lack of overlap with prior and ongoing work through literature review, discussions with study chair(s) and the disease committee.
  3. Confirm data elements are available  
*(This will be covered at the end of the presentation.)*
  4. Review by the Disease Committee Chair

Title of Data Project:

Name of Requestor:

Requestor's Email Address & Telephone Number:

Name of Requestor's Institution:

Address of Requestor's Institution:

Requestor understands requested Data will be provided to Requestor at Requestor's Institution:

Yes  No

SWOG Clinical trial(s) from which Data is requested:

Has primary manuscript(s) of the SWOG Clinical trial(s) from which Data is requested been published:

Yes  No

Data Project objective(s):

Primary objective:

Secondary objective(s):

Brief Justification:

Rationale:

Background:

Significance:

Endpoints:

Primary endpoint:

Secondary endpoint(s):

Approach / Methods:

Statistical Plan:

Is this Data Sharing Request a collaborative effort involving additional Investigator(s) and / or Institutions(s):

Yes  No

If Yes, name participating Investigator(s) and Institution(s):

Investigator and Institution:



# Publications using SWOG Data

- Prior to submission, all abstracts and manuscripts must be forwarded to the SWOG Publications Office ([pubs@swog.org](mailto:pubs@swog.org)) to ensure compliance with Group policy.
- Abstracts prepared for submission to any society meetings or seminars must be submitted to the Publications Office **no later than two weeks prior to submission**, or as determined by contractually bound timelines, to allow for authorship review and circulation to appropriate reviewers.



# SWOG Data Request Process

- See [SWOG Policy No. 43](#) for more information.
- SWOG Policies are publicly available on [SWOG.org](http://swog.org).

**SWOG CANCER RESEARCH NETWORK**  
<http://swog.org>

<p><b>Policy Memorandum No. 43</b>  <b>Subject:</b> Requests for Participant Data  <b>Departments Affected:</b> All</p>	<p><b>Page 1 of 5 pages</b>  <b>Original Release Date:</b> April 2006  <b>Revision Date:</b> October 2019</p>
---	---

**REQUESTS FOR PATIENT DATA  
FROM SWOG STUDIES**

1. Introduction.....	1
2. Data Sharing .....	2
3. Guidelines for the Availability of Data Sets.....	2
4. Request Procedures .....	2
5. Data Abstractions .....	3
6. Regulatory Considerations.....	3
7. Release Conditions .....	4
8. Fees.....	4
9. Appeals Process .....	5



# NCTN/NCORP Data Archive

- NCTN/NCORP Data Archive is another resource for research proposals.
- Includes SWOG and **non-SWOG** coordinated trials.
- The archive contains clinical data from Phase II/III, Phase III, and select Phase II studies from:
  - Primary publications published after January 2015.
  - Non-primary publications presenting updated survival data published after April 2018.
- Search for and request NCI-sponsored clinical data here:  
<https://nctn-data-archive.nci.nih.gov/>
- A signed DUA with the NCI is required to access the data. A SWOG agreement is not needed.



# SWOG.org Clinical Trials Search Tool

- How do you find trials that match your research goals?
- What data are available for those trials?

Member Resources | SWOG | CANCER RESEARCH NETWORK

About The SWOG Network News & Events Clinical Trials **Member Resources** For Patients

Member Resources

Advocate Resources  
BMT Facility List  
Breast Cancer Commons  
CRA Workbench  
Digital Engagement  
Hope Funding Opportunities  
Membership +  
Oncology Research Professionals  
Pharmaceutical Sciences  
Protocol Tracking Reports  
Publications & Presentations  
Radiation Therapy Facility List  
Recruitment & Retention

SWOG / Member Resources

## Member Resources

Your place to get tools and information for SWOG Cancer Research Network trials.

### Tools

**Clinical Trials** →

CRA Workbench →

Member Directory →

SWOG Meetings →

Clinical Trials | SWOG | CANCER RESEARCH NETWORK

About The SWOG Network News & Events **Clinical Trials** Member Resources For Patients

Clinical Trials

Biospecimen Resources  
Clinical Research Resources  
**Clinical Trials Search**  
Frequently Asked Questions  
Publications  
Institutions  
Pharmacies  
Quality Assurance & Audits  
Serious Adverse Events  
Training Resources  
Contracts & Budgets  
CRA Workbench  
Protocol Workbench  
Accrual Resources

SWOG / Clinical Trials

## Clinical Trials

SWOG Cancer Research Network is one of the first cooperative groups created by the National Cancer Institute. SWOG trials seek to improve medical care through symptom control and quality of life.

# SWOG.org - Searching for Clinical Trials: Filters

The screenshot shows the SWOG.org Clinical Trials search interface. At the top, there is a search bar and navigation links: About, The SWOG Network, News & Events, Clinical Trials, Member Resources, and For Patients. Below the navigation, the page title is "Clinical Trials Search". The search filters section includes:

- Keywords/SWOG Study Number:
- Area of Research:
- SEARCH button
- More filters + button (highlighted with a red box and arrow)
- Accrual Status:  Any,  Open,  Closed
- Limit to SWOG Trials:  All Trials,  SWOG Trials Only
- Show only published studies

Below the filters, it shows "1026 Results" and a list of clinical trials. The first result is:

**1026 Results** VIEW

Open	Phase	Accrual	SWOG Clinical Trial Number	Save to List	None
<input checked="" type="radio"/>	-	0%	S1900K		
<b>A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)</b>					
<b>Status Notes</b> S1900K will open to accrual December 18, 2023, effective 3:00 p.m. EST.					
<b>Research Committee(s)</b> LungMAP					
<b>Study Chair(s)</b> Paul K. Paik, MD					
<b>Activated</b> 12-18-2023					
<b>ClinicalTrials.gov Registry Number</b> NCT06031688					

The second result is:

Open	Phase	Accrual	SWOG Clinical Trial Number	Save to List	None
<input checked="" type="radio"/>	-	0%	S2213		
<b>A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis</b>					

The screenshot shows the SWOG.org Clinical Trials search interface with the filters expanded. At the top, there is a search bar and navigation links: About, The SWOG Network, News & Events, Clinical Trials, Member Resources, and For Patients. Below the navigation, the page title is "Clinical Trials Search". The search filters section includes:

- Keywords/SWOG Study Number:
- Area of Research:
- SEARCH button
- Fewer filters - button
- Accrual Status:  Any,  Open,  Closed
- Limit to SWOG Trials:  All Trials,  SWOG Trials Only
- Show only published studies
- Study Type:
- Treatment:
- Study Chair:
- Participating Institution:
- Phase:
- Cancer Control Subcommittee:
- Study Sponsor:
- FDA Registration Trial
- Uses PRO Forms

Below the filters, it shows "1026 Results" and a list of clinical trials. The first result is:

**1026 Results** VIEW

Open	Phase	Accrual	SWOG Clinical Trial Number	Save to List	None
<input checked="" type="radio"/>	-	0%	S1900K		





# SWOG.org - Searching for Clinical Trials: Filters

**Clinical Trials**

Keywords/SWOG Study Number

Area of Research **Area of Research**

SEARCH Fewer filters

Accrual Status  Any  Open  Closed  Limited

Study Type

Phase

Study Chair

Participating Institution

Study Sponsor   FDA Registration Trial  Uses PRO Forms

1025 Results VIEW

**S2213 SWOG Clinical Trial Number** Save to List

**A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis**

**Accrual** 0%

**Status Notes** S2213 is open to patient accrual December 01, 2023, effective 12:00 p.m. Pacific Time.

Research Committee(s)	Myeloma
Activated	12-01-2023
ClinicalTrials.gov Registry Number	06022939



# SWOG.org - Searching for Clinical Trials: Filters

**Clinical Trials**

Keywords/SWOG Study Number:  Area of Research:  **SEARCH** Fewer filters -

Accrual Status:  Any  Open  Closed Limit to SWOG Trials:  All Trials  SWOG Trials Only Show only published studies

Study Type:  Treatment:  Study Chair:  Participating Institution:

Cancer Control Subcommittee:  Study Sponsor:   FDA Registration Trial  Uses PRO Forms

VIEW

**Open Phase** **S2213 SWOG Clinical Trial Number** Save to List

**0%**  
Accrual

**A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis**

Status Notes: S2213 is open to patient accrual December 01, 2023, effective 12:00 p.m. Pacific Time.

Research Committee(s): Myeloma

Activated: 12-01-2023

ClinicalTrials.gov Registry Number: 06022939



# SWOG.org - Searching for Clinical Trials: Filters

**Clinical Trials**

Keywords/SWOG Study Number:  Area of Research:  **SEARCH** Fewer filters

Accrual Status:  Any  Open  Closed **Limit to SWOG Trials**:  All Trials  SWOG Trials Only  Show only published studies

Study Type:  Treatment:  Study Chair:  Participating Institution:

Phase:  Study Sponsor:   FDA Registration Trial  Uses PRO Forms

**1025 Results** **VIEW**

**S2213 SWOG Clinical Trial Number** Save to List:

**0%** Accrual

**A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis**

Status Notes	S2213 is open to patient accrual December 01, 2023, effective 12:00 p.m. Pacific Time.
Research Committee(s)	Myeloma
Activated	12-01-2023
ClinicalTrials.gov Registry Number	06022939



# SWOG.org - Searching for Clinical Trials: Filters

**Clinical Trials**

Keywords/SWOG Study Number:  Area of Research:  **SEARCH** Fewer filters

Accrual Status:  Any  Open  Closed Limit to SWOG Trials:  All Trials  SWOG Trials Only Show only published studies

Study Type:  Treatment:  Study Chair:  Participating Institution:

Phase:  Cancer Control Subcommittee:  Study Sponsor:   FDA Registration Trial  Uses PRO Forms

VIEW

SWOG Clinical Trial Number:  Save to List:

**0%**  
Accrual

**A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis**

Status Notes: 52213 is open to patient accrual December 01, 2023, effective 12:00 p.m. Pacific Time.

Research Committee(s): Myeloma

Activated: 12-01-2023

ClinicalTrials.gov Registry Number: 06022939



# SWOG.org - Searching for Clinical Trials: Filters

## Clinical Trials

Keywords/SWOG Study Number  Area of Research   Fewer filters

Accrual Status  Any  Open  Closed Limit to SWOG Trials  All Trials  SWOG Trials Only Show only published studies

Study Type  Treatment  Study Chair  Participating Institution

Phase  Cancer Control Subcommittee  Study Sponsor   FDA Registration Trial  Uses PRO Forms

1025 Results

Open Phase

0% Accrual

**S2213 SV**

### A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Status Notes S2213 is open to patient accrual December 01, 2023, effective 12:00 p.m. Pacific Time.

Research Committee(s) Myeloma

Activated 12-01-2023

ClinicalTrials.gov Registry Number 06022939



# SWOG.org - Searching for Clinical Trials: Filters

**Clinical Trials**

Keywords/SWOG Study Number:  Area of Research:  **SEARCH** Fewer filters

Accrual Status:  Any  Open  Closed Limit to SWOG Trials:  All Trials  SWOG Trials Only Show only published studies

Study Type:  Treatment:  Study Chair:  Participating Institution:

Phase:  Cancer Control Subcommittee:  Study Sponsor:   FDA Registration Trial  Uses PRO Forms

**1025 Results** VIEW

**S2213 SWOG Clinical Trial Number** Save to List

**Open**  **Phase**

**0%**  
Accrual

**A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis**

**Status Notes** S2213 is open to patient accrual December 01, 2023, effective 12:00 p.m. Pacific Time.

**Research Committee(s)** Myeloma

**Activated** 12-01-2023

**ClinicalTrials.gov Registry Number** 06022939

# SWOG.org – Identifying the Primary Statistician for a SWOG-led study

S2213 SWOG Clinical Trial Number

Open Phase Save to List None

0% Accrual


A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Status Notes	S2213 is open to patient accrual December 01, 2023, effective 12:00 p.m. Pacific Time.
Research Committee(s)	Myeloma
Activated	12-01-2023
ClinicalTrials.gov Registry Number	06022939

The Research Committee under which the primary clinical trial was conducted will be identified on the protocol abstract page on SWOG.org, as shown here.

- First, identify the Research Committee that is associated with the conduct of the primary clinical trial via the protocol abstract page on SWOG.org.
- The contact information for the Primary Statistician that supports the associated Research Committee can be found via the [Staff webpage on SWOG.org](#).

# SWOG.org – Identifying the Primary Statistician for a SWOG-led study



From SWOG.org, navigate to:  
“The SWOG Network” >> “Our Staff”

## SWOG Cancer Research Network Statistics and Data Management Center -

Fred Hutchinson Cancer Center  
1100 Fairview Avenue North, M3-C102  
Seattle, WA [98109-1024](#)  
Phone: [206-667-4623](#)  
Fax: [206-667-4408](#)

Cancer Research And Biostatistics  
1505 Westlake Ave N, Ste 750  
Seattle, WA 98109  
Phone: [206-652-9711](#)

- After identifying the Research Committee associated with the primary clinical trial:
  - The name and contact email for the Primary Statistician that supports the associated Research Committee is available via the [Staff webpage on SWOG.org](#) under the *SWOG Statistics and Data Management Center* office locations.
  - Note: Primary Statisticians work out of both the Fred Hutchinson Cancer Center (under Biostatistics Faculty) and Cancer Research and Biostatistics (under Biostatistics) locations.





# SWOG.org Search Results

Includes ct.gov registry number.

9 Results

**S2104 SWOG Clinical Trial Number**

**A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors**

Research Commitment: Gastrointestinal Cancer  
 Study Chair(s): Melissa Pardo-Seco, MD, PhD  
 Activated: 10-14-2021

**S2001 SWOG Clinical Trial Number**

**Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects**

Status Notes: Activation Effective 12-04-2020 3:00 pm eastern  
 Research Commitment: Gastrointestinal Cancer  
 Study Chair(s): Vincent Chung, MD  
 Activated: 12-04-2020  
 ClinicalTrials.gov Registry Number: NCT04548752


"Table view" is condensed

Indicates whether the study has been published.

9 Results

Status	Trial Number	Title	Activated	Closed	Accrual	Phase	Published
Open	S2104	A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors	10/14/2021		20%		
Closed	S0629	A Phase II Trial of S-Fluorouracil Plus TTK635 in Patients with Advanced Pancreas Cancer	5/15/1997	3/15/1999	100%		✓
Closed	S8700	PANCREAS	9/15/1997	6/10/2001	90%		✓
Closed	S0624	PANCREAS	6/1/2000	6/1/2001	97%		✓
Closed	S0187	PANCREAS	7/1/2001	6/1/2003	100%		✓
Open	S2001	Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects	12/4/2020		31%		
Closed	S1505	Peroperative FOLFIRINOX vs Gem/Tab-Pac for Resectable Panc Adeno	10/12/2015		96%		
Closed	S1115	Randomized Phase II of AZD-6244 add MK-2206 vs mFOLFIRINOX in Pts with Met Pancreatic Cancer After Chemo	8/15/2012	5/15/2014	100%		✓
Closed	S1513	8P in 2nd Line FOLFIRINOX or w/o Veliparib (ABT788) in met panc cancer	6/1/2016		86%		

# Clinical Trial Listing



Accrual

discontinue the experimental treatment but may continue on FOLFIRI alone. Patients on both arms should continue study follow-up.

Activated	09/01/2016
Participants	ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

## Research committees

Gastrointestinal Cancer

## Treatment

5-Fluorouracil Irinotecan Leucovorin Calcium ABT-888

## Research committees

Gastrointestinal Cancer

## Treatment

5-Fluorouracil Irinotecan Leucovorin Calcium ABT-888

## Eligibility Criteria -

Histologically or cytologically documented pancreatic adenocarcinoma. Pancreatic neuroendocrine tumors, lymphoma of the pancreas, or ampullary cancer are not eligible; Must have metastatic disease that is measurable, CT scans or MRIs of the chest, abdomen, and pelvis used to assess measurable disease must have been completed within 28 days prior to reg. CT Scans or MRIs used to assess non-measurable disease must have been completed within 42 days prior to reg.

Must not have history of brain mets; must have had one and only one prior regimen of systemic therapy for metastatic disease unless the patient received systemic therapy with gemcitabine/nab-paclitaxel for resectable or borderline/locally advanced unresectable disease and progressed with metastatic disease within 3 months of the past dose of systemic therapy; systemic therapy and chemoradiotherapy for tx of resectable, borderline resectable or locally advanced unresectable disease is allowed and does not count toward prior therapy for metastatic disease; must have completed systemic therapy at least 14 days prior to reg, any surgical procedure must have been

## Eligibility Criteria +

## Publication Information -

### 2021

[Randomized Phase II Study of PARP Inhibitor ABT-888 \(Veliparib\) with Modified FOLFIRI versus FOLFIRI as Second Line Treatment of Metastatic Pancreatic Cancer: SWOG S1513](#)

EG Chiorean;K Guthrie;P Philip;E Swisher;F Jalikis;M Pishvaian;J Berlin;M Nos;J Suga;I Garrido-Laguna;D Cardin;M Radke;M Duong;A Lowy;H Hochster Clinical Cancer Research, Dec 1;27(23):6314-6322

PMid: PMID34580114 | PMC number: PMC8639715

### 2020

[Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-world Experiment](#)

DD Kim;G Guzauskas;C Bennette;A Basu;D Veenstra;S Ramsey;JJ Carlson PharmacoEconomics Feb;38(2):171-179; 2019 Oct 21. doi: 10.1007/s40273-019-00848-8. [Epub ahead of print]

Publications link to papers



# CTSU.org Website Access

- Site staff set up their CTEP-IAM account, register with Registration and Credentialing Repository (RCR), and ID.me
- To obtain/update CTEP-IAM account: <https://ctepcore.nci.nih.gov/iam>
- To register in the RCR: <https://ctepcore.nci.nih.gov/rcr>
- To set up ID.me account:  
[https://ctep.cancer.gov/investigatorResources/NCI\\_CTEP\\_IAM\\_User\\_Access\\_Update.htm](https://ctep.cancer.gov/investigatorResources/NCI_CTEP_IAM_User_Access_Update.htm)
- RCR Quick Reference Guide – Provides an overview of the CTEP-IAM and RCR registration process

# Accessing Protocol-Specific information on CTSU.org

Search protocol titles or numbers... Go!

All Protocols

- My Protocols ?
- By Site
- By Lead Organization
- By Cancer Type
- By Study Type
- By Phase
- AYA (NCTN)
- NCTN
- Precision Medicine Protocols (
- ETCTN
- NCORP
- NCI
- CCDR
- NINT
- CITN
- Archived Protocols
- Reports
  - Accrual Reports
  - Study Agent
  - IBCSG Query and Delinquency Reports

**Search for protocols by title or protocol number OR browse for the protocol number in the left navigation pane.**

Documents>>CIRB-approved Documents tab includes: Protocol and Consent Documents>>Protocol-Related Documents tab: includes: Case Report Forms and Memos

Home Funding Information Documents Protocol Requirements

NCI Community Oncology Research Program S2205

Ice Compress: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy

For site registration approval, at least one staff member must complete each of the four required Training Courses in CLASS. A link to the courses in CLASS is located in Protocol Related Documents, use the Document Type filter and select Education and Promotion or Site Registration.

#	Document Title	Document Date	Format	Post Date
1	Protocol Version Date 03/09/23	16-Mar-2023		
2	Consent Form (PVD 03/09/23)	16-Mar-2023		

Document Type: Case Report Forms

#	Document Title	Document Type	Document Date	Format	Post Date
1	Master Forms Set	Case Report Forms	15-Jan-2024	PDF	17-Jan-2024



# Master Forms Set from a SWOG Trial

## SWOG S2205 ONSTUDY FORM

Patient Identifier       Study Identifier  S  2  2  0  5 Registration Step  1

Patient Initials \_\_\_\_\_ (L, F M)

**Page: Onstudy: Participant and Disease Description**

**Instructions:** Submit this form within 15 days of initial registration. Date is in **DD MON YYYY** format. Explain any blank fields or blank dates in the **Comments** section.

**Performance Status**  0  1  2  3  4

**Height**    cm

**Weight**    .  kg

**What was the date of the history and physical exam?**

**What was the date of the initial diagnosis of the solid tumor malignancy for which the participant is planning to receive taxane-based chemotherapy?**

**What is the type of tumor for which the participant is receiving taxane-based chemotherapy?**

Breast  
 Lung  
 Endometrium  
 Ovary  
 Other, specify \_\_\_\_\_

**Did the participant have a history of skin or limb metastases?**  Yes  No

**Did the participant previously receive neurotoxic chemotherapy? (e.g. taxanes, platinum agents, vinca alkaloids, or bortezomib)**  Yes  No

**Did the participant have pre-existing clinical peripheral neuropathy?**  Yes  No

**Did the participant have a history of Raynaud's phenomenon?**  Yes  No

**Did the participant have a history of cold agglutinin disease?**  Yes  No

**Did the participant have a history of cryoglobulinemia?**  Yes  No

**Did the participant have a history of cryofibrinogenemia?**  Yes  No

**Did the participant have a history of post-traumatic cold dystrophy?**  Yes  No

**Did the participant have a history of peripheral arterial ischemia?**  Yes  No

**Did the participant have any open skin wounds or ulcers of the limbs?**  Yes  No

## SWOG S2205 TREATMENT

Participant Identifier       Study Identifier  S  2  2  0  5 Registration Step  1

Participant Initials \_\_\_\_\_ (L, F M) Cycle Number

**Page: Treatment**

**TREATMENT FOR THIS CYCLE**

If any assigned agent was not administered during this cycle, then leave Start Date and End Date empty, enter "0" for the total dose administered and complete the Treatment Adjustments form. If any assigned agent was withdrawn in a previous cycle, enter "No" for dose modifications and enter "0" for the planned doses and the total dose administered.

Treatment Name	Start Date	End Date	Planned Dose Per Administration	Planned Total Dose	Total Dose Administered
Paclitaxel	<input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	<input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	<input type="text"/> <input type="text"/> mg/m <sup>2</sup>	<input type="text"/> <input type="text"/> . <input type="text"/> mg	<input type="text"/> <input type="text"/> . <input type="text"/> mg
Carboplatin	<input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	<input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	<input type="text"/> <input type="text"/> . <input type="text"/> mg	<input type="text"/> <input type="text"/> . <input type="text"/> mg	<input type="text"/> <input type="text"/> . <input type="text"/> mg
Docetaxel	<input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	<input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	<input type="text"/> <input type="text"/> mg/m <sup>2</sup>	<input type="text"/> <input type="text"/> . <input type="text"/> mg	<input type="text"/> <input type="text"/> . <input type="text"/> mg
Nab-Paclitaxel	<input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	<input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	<input type="text"/> <input type="text"/> mg/m <sup>2</sup>	<input type="text"/> <input type="text"/> . <input type="text"/> mg	<input type="text"/> <input type="text"/> . <input type="text"/> mg

**Will the participant continue to receive taxane therapy?**  Yes  No



SWOG is committed to sharing data.

To ensure a successful data request application, do your homework to make certain that the proposal is sound and feasible.